INVEGA SUSTENNA

Peak

paliperidone palmitate

NDAINTRAMUSCULARSUSPENSION, EXTENDED RELEASE
Approved
Jul 2009
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20

Mechanism of Action

[see ] . Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone is unclear. However, the drug's therapeutic effect in schizophrenia could be mediated through a combination of central dopamine Type 2 (D 2 ) and serotonin Type 2 (5HT 2A ) receptor…

Clinical Trials (5)

NCT04940039Phase 4Completed

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings

Started Jul 2021
93 enrolled
Schizophrenia
NCT04572685Phase 1Completed

Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

Started Jan 2020
36 enrolled
Schizophrenia Patients
NCT04072575Phase 3Completed

A Study of Paliperidone Palmitate 6-Month Formulation

Started Sep 2019
178 enrolled
Schizophrenia
NCT03809325N/ACompleted

A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly

Started Nov 2018
225 enrolled
Schizophrenia
NCT03713658Phase 4Completed

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

Started Oct 2018
34 enrolled
Schizophrenia

Loss of Exclusivity

LOE Date
Jan 26, 2031
59 months away
Patent Expiry
Jan 26, 2031

Patent Records (1)

Patent #ExpiryTypeUse Code
9439906
Jan 26, 2031
U-2757